Moody's Investors Service is adding to the bummer. Moody's reiterated its negative view for the pharma industry, saying that its view "reflects the sector's increasing exposure to major patent expirations, peaking in 2011 and 2012, at a time when the quality of late-stage pipelines is on average insufficient to offset this trend.
via fiercepharma.com
No comments:
Post a Comment